Literature DB >> 3571433

Increased spontaneous immunoglobulin secretion associated with cyclophosphamide-induced immune suppression.

O Martínez-Maza, D J Moody, A R Rezai, G W Ellison, L W Myers, W W Tourtellotte, J L Fahey.   

Abstract

Spontaneous immunoglobulin (Ig) secretion by cells from multiple sclerosis (MS) patients (in the progressive phase) treated with monthly pulse doses of cyclophosphamide (CY) (1000-1600 mg/M2) was measured using the protein A plaque assay, to evaluate the effect of CY treatment on B-cell function. Surprisingly, an increase, rather than a decrease, in Ig-secreting cells was seen following CY treatment. CY-treated MS patients averaged 1380 +/- 535 spontaneous total (IgM + G + A) Ig plaque-forming cells (PFC) per 1 X 10(6) peripheral blood mononuclear cells (MNC), measured at 15-22 days after monthly CY administration, while healthy adults had 280 +/- 47 Ig PFC/10(6) MNC, and MS patients not treated with CY had 300 +/- 43 Ig PFC/10(6) MNC. The observed increase was due to an increase in IgG and IgA PFC. PFC levels remained elevated for 4 weeks following CY treatment, decreasing to control levels by 7-8 weeks post-CY. A small increase in serum IgG level was noted after greater than 12 months of pulse CY therapy; no increase was seen in CSF IgG levels. A preferential decrease in the number of CD4+ T cells was also seen in the CY-treated MS patients. We propose that the observed increase in the number of spontaneous Ig PFC was due to the CY-induced disruption of the CD4+ T cell-mediated control of in vivo activated B cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3571433     DOI: 10.1007/bf00916004

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  22 in total

Review 1.  A new approach to the study of human B lymphocyte function using an indirect plaque assay and a direct B cell activator.

Authors:  A G Bird; S Britton
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

2.  T-cell control of Epstein-Barr virus-infected B cells is lost during P. falciparum malaria.

Authors:  H C Whittle; J Brown; K Marsh; B M Greenwood; P Seidelin; H Tighe; L Wedderburn
Journal:  Nature       Date:  1984 Nov 29-Dec 5       Impact factor: 49.962

3.  Evidence for the ontogenic precedence of suppressor T cell functions in the human neonate.

Authors:  U Andersson; S Britton; M De Ley; G Bird
Journal:  Eur J Immunol       Date:  1983-01       Impact factor: 5.532

Review 4.  Modulation of the immune response by chemotherapy.

Authors:  D P Braun; J E Harris
Journal:  Pharmacol Ther       Date:  1981       Impact factor: 12.310

5.  Spontaneous production of interferon-gamma in adult and newborn humans.

Authors:  O Martinez-Maza; U Andersson; J Andersson; S Britton; M De Ley
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

6.  The suppression of Epstein-Barr virus infection in vitro occurs after infection but before transformation of the cell.

Authors:  D A Thorley-Lawson
Journal:  J Immunol       Date:  1980-02       Impact factor: 5.422

7.  Activation of human B lymphocytes. XII. Differential effects of in vitro cyclophosphamide on human lymphocyte subpopulations involved in B-cell activation.

Authors:  H C Stevenson; A S Fauci
Journal:  Immunology       Date:  1980-03       Impact factor: 7.397

8.  Quantitative changes in T helper or T suppressor/cytotoxic lymphocyte subsets that distinguish acquired immune deficiency syndrome from other immune subset disorders.

Authors:  J L Fahey; H Prince; M Weaver; J Groopman; B Visscher; K Schwartz; R Detels
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

9.  Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome.

Authors:  H C Lane; H Masur; L C Edgar; G Whalen; A H Rook; A S Fauci
Journal:  N Engl J Med       Date:  1983-08-25       Impact factor: 91.245

10.  Characteristics of Epstein-Barr virus activation of human B lymphocytes.

Authors:  A G Bird; S Britton; I Ernberg; K Nilsson
Journal:  J Exp Med       Date:  1981-09-01       Impact factor: 14.307

View more
  3 in total

1.  Serological Assessment of 18 Pathogens and Risk of AIDS-Associated Non-Hodgkin Lymphoma.

Authors:  Gordana Halec; Tim Waterboer; Nicole Brenner; Julia Butt; W David Hardy; Gypsyamber DʼSouza; Steven Wolinsky; Bernard J Macatangay; Michael Pawlita; Roger Detels; Otoniel Martínez-Maza; Shehnaz K Hussain
Journal:  J Acquir Immune Defic Syndr       Date:  2019-03-01       Impact factor: 3.771

Review 2.  The Role of Microbial Translocation and Immune Activation in AIDS-Associated Non-Hodgkin Lymphoma Pathogenesis: What Have We Learned?

Authors:  Marta Epeldegui; Shehnaz K Hussain
Journal:  Crit Rev Immunol       Date:  2020       Impact factor: 1.735

Review 3.  Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments.

Authors:  Mickael Bonnan
Journal:  Mult Scler Int       Date:  2015-01-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.